Merck KGaA (0O14) Share Forecast & Price Target

Compare

9 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0O14 Analyst Ratings

Moderate Buy

5 Buy

2 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Merck

KGaA

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0O14 Stock 12 Month Forecast

Average Price Target

€149.00

▲(21.19% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Merck KGaA in the last 3 months. The average price target is €149.00 with a high forecast of €182.00 and a low forecast of €130.00. The average price target represents a 21.19% change from the last price of €122.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"106":"€106","183":"€183","125.25":"€125.3","144.5":"€144.5","163.75":"€163.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€182.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":149,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€149.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€130.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[106,125.25,144.5,163.75,183],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.2,130.4923076923077,134.7846153846154,139.0769230769231,143.36923076923077,147.66153846153847,151.95384615384614,156.24615384615385,160.53846153846155,164.83076923076925,169.12307692307692,173.41538461538462,177.7076923076923,{"y":182,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.2,127.95384615384616,129.7076923076923,131.46153846153845,133.2153846153846,134.96923076923076,136.72307692307692,138.47692307692307,140.23076923076923,141.98461538461538,143.73846153846154,145.4923076923077,147.24615384615385,{"y":149,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.2,126.49230769230769,126.78461538461539,127.07692307692308,127.36923076923077,127.66153846153847,127.95384615384616,128.24615384615385,128.53846153846155,128.83076923076922,129.12307692307692,129.41538461538462,129.7076923076923,{"y":130,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":133.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.15,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.45,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.45,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€182.00

Average Price Target€149.00

Lowest Price Target€130.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Weston

UBS

€150

Buy

22.00%

Upside

Reiterated

03/05/26

UBS Keeps Their Buy Rating on Merck KGaA (0O14)

Richard Vosser

J.P. Morgan

€150

Buy

22.00%

Upside

Reiterated

03/05/26

J.P. Morgan Sticks to Its Buy Rating for Merck KGaA (0O14)

James Quigley

Goldman Sachs

€150

Buy

22.00%

Upside

Reiterated

03/05/26

Merck KGaA (0O14) Gets a Buy from Goldman Sachs

Charles Pitman CFA

Barclays

€130

Hold

5.73%

Upside

Reiterated

02/03/26

Barclays Remains a Hold on Merck KGaA (0O14)

Peter Spengler

DZ BANK AG

―

Buy

―

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Merck KGaA (LSE: GB:0O14) and Moderna (NASDAQ: MRNA)

Falko Friedrichs

Deutsche Bank

€127→€132

Hold

7.36%

Upside

Downgraded

02/03/26

Deutsche Bank downgrades Merck KGaA (0O14) to a Hold

David Evans

Kepler Capital

€182

Buy

48.03%

Upside

Reiterated

01/20/26

Kepler Capital Remains a Buy on Merck KGaA (0O14)

Thibault Boutherin

Morgan Stanley

€130→€135

Hold

9.80%

Upside

Reiterated

12/03/25

Morgan Stanley Remains a Hold on Merck KGaA (0O14)

Florent Cespedes

Bernstein

€138→€135

Hold

9.80%

Upside

Reiterated

11/17/25

Bernstein Reaffirms Their Hold Rating on Merck KGaA (0O14)

Dylan Van Haaften

Stifel Nicolaus

€105

Sell

-14.60%

Downside

Reiterated

11/13/25

Cautious Outlook for Merck KGaA Amidst Unchanged Guidance and Growth Concerns

Peter Verdult

Exane BNP Paribas

€107

Sell

-12.97%

Downside

Initiated

04/16/25

BNP Paribas Exane Starts Merck KGaA (MRK:GR) (MKGAF) at UnderperformBNP Paribas Exane analyst Peter Verdult initiates coverage on Merck KGaA (MRK:GR) (OTC: MKGAF) with a Underperform rating and a price target of EUR107.00.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Weston

UBS

€150

Buy

22.00%

Upside

Reiterated

03/05/26

UBS Keeps Their Buy Rating on Merck KGaA (0O14)

Richard Vosser

J.P. Morgan

€150

Buy

22.00%

Upside

Reiterated

03/05/26

J.P. Morgan Sticks to Its Buy Rating for Merck KGaA (0O14)

James Quigley

Goldman Sachs

€150

Buy

22.00%

Upside

Reiterated

03/05/26

Merck KGaA (0O14) Gets a Buy from Goldman Sachs

Charles Pitman CFA

Barclays

€130

Hold

5.73%

Upside

Reiterated

02/03/26

Barclays Remains a Hold on Merck KGaA (0O14)

Peter Spengler

DZ BANK AG

―

Buy

―

Reiterated

02/03/26

Analysts Offer Insights on Healthcare Companies: Merck KGaA (LSE: GB:0O14) and Moderna (NASDAQ: MRNA)

Falko Friedrichs

Deutsche Bank

€127→€132

Hold

7.36%

Upside

Downgraded

02/03/26

Deutsche Bank downgrades Merck KGaA (0O14) to a Hold

David Evans

Kepler Capital

€182

Buy

48.03%

Upside

Reiterated

01/20/26

Kepler Capital Remains a Buy on Merck KGaA (0O14)

Thibault Boutherin

Morgan Stanley

€130→€135

Hold

9.80%

Upside

Reiterated

12/03/25

Morgan Stanley Remains a Hold on Merck KGaA (0O14)

Florent Cespedes

Bernstein

€138→€135

Hold

9.80%

Upside

Reiterated

11/17/25

Bernstein Reaffirms Their Hold Rating on Merck KGaA (0O14)

Dylan Van Haaften

Stifel Nicolaus

€105

Sell

-14.60%

Downside

Reiterated

11/13/25

Cautious Outlook for Merck KGaA Amidst Unchanged Guidance and Growth Concerns

Peter Verdult

Exane BNP Paribas

€107

Sell

-12.97%

Downside

Initiated

04/16/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck KGaA

3 Months

xxx

Success Rate

23/35 ratings generated profit

Average Return

+4.39%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.71% of your transactions generating a profit, with an average return of +4.39% per trade.

1 Year

Peter SpenglerDZ BANK AG

Success Rate

23/35 ratings generated profit

Average Return

+10.16%

a rating ―

Copying Peter Spengler's trades and holding each position for 1 Year would result in 65.71% of your transactions generating a profit, with an average return of +10.16% per trade.

2 Years

xxx

Success Rate

23/35 ratings generated profit

Average Return

+19.19%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 65.71% of your transactions generating a profit, with an average return of +19.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0O14 Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0O14 has received 10 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 0O14 average Analyst price target in the past 3 months is 149.00.

Each month's total comprises the sum of three months' worth of ratings.

0O14 Financial Forecast

0O14 Earnings Forecast

Next quarter’s earnings estimate for 0O14 is €1.92 with a range of €1.86 to €1.98. The previous quarter’s EPS was €1.88. 0O14 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 0O14 has Performed in-line its overall industry.

0O14 Sales Forecast

Next quarter’s sales forecast for 0O14 is €5.02B with a range of €4.97B to €5.08B. The previous quarter’s sales results were ―. 0O14 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 0O14 has Performed in-line its overall industry.

0O14 Stock Forecast FAQ

What is GB:0O14’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck KGaA’s 12-month average price target is 149.00.

What is GB:0O14’s upside potential, based on the analysts’ average price target?

Merck KGaA has 21.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Merck KGaA a Buy, Sell or Hold?

Merck KGaA has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 2 hold ratings and 0 sell ratings.

What is Merck KGaA’s share price target?

The average share price target for Merck KGaA is 149.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €182.00 ,and the lowest forecast is €130.00. The average share price target represents 21.19% Increase from the current price of €122.95.

What do analysts say about Merck KGaA?

Merck KGaA’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Merck KGaA?

To buy shares of GB:0O14, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Merck KGaA (0O14) Share Forecast & Price Target

0O14 Analyst Ratings

0O14 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck KGaA

0O14 Analyst Recommendation Trends

0O14 Financial Forecast

0O14 Earnings Forecast

0O14 Sales Forecast

0O14 Stock Forecast FAQ

Detailed List of Analyst Forecasts